Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phototype-related Trichoscopic differences in lichen Planopilaris and frontal Fibrosing alopecia.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

KCNQ1 rs163184 Variant Modulates Susceptibility to Classic and DPP-4 Inhibitor-Associated Bullous Pemphigoid.

International journal of dermatology·2026
Same author

Treatment-associated phenotype switching between psoriasis and atopic dermatitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Trichoscopy of Cicatricial Alopecia in Fair and Dark Skin: A Multicenter International Study of the EADV Task Force on Hair Diseases and the IDS Task Force on Trichoscopy.

International journal of dermatology·2026
Same author

Clinical outcomes of adalimumab treatment in dissecting cellulitis, along with pre- and post-treatment trichoscopic findings: A retrospective, multicentre study of 29 cases.

Journal of the American Academy of Dermatology·2026
Same author

Apremilast for Recalcitrant Erythema Nodosum: A Case Series.

International journal of dermatology·2026

Related Experiment Video

Updated: May 15, 2026

Auricular Point Acupressure Therapy: A Safe and Effective Treatment for Postsurgical Abortion Recovery
07:28

Auricular Point Acupressure Therapy: A Safe and Effective Treatment for Postsurgical Abortion Recovery

Published on: February 3, 2026

Spontaneous abortion during ustekinumab therapy.

Christina Fotiadou1, Elizabeth Lazaridou, Eleni Sotiriou

  • 1First Department of Dermatology-Venereology, Aristotle University Medical School, Thessaloniki, Greece.

Journal of Dermatological Case Reports
|January 19, 2013
PubMed
Summary

This case report examines a pregnancy outcome in a woman with psoriasis treated with ustekinumab. The patient experienced a spontaneous abortion, highlighting the need for more research on ustekinumab safety in pregnancy.

Keywords:
abortionbiologic agentspregnancy outcomespsoriasisustekinumab

Related Experiment Videos

Last Updated: May 15, 2026

Auricular Point Acupressure Therapy: A Safe and Effective Treatment for Postsurgical Abortion Recovery
07:28

Auricular Point Acupressure Therapy: A Safe and Effective Treatment for Postsurgical Abortion Recovery

Published on: February 3, 2026

Area of Science:

  • Dermatology
  • Obstetrics & Gynecology
  • Pharmacology

Background:

  • Psoriasis impacts women of reproductive age, with limited data on pregnancy prognosis.
  • Emerging biologic therapies like ustekinumab for psoriasis raise safety concerns during pregnancy.

Observation:

  • A 35-year-old female psoriasis patient, treated with ustekinumab for one year, became pregnant inadvertently.
  • Ustekinumab was discontinued immediately; the patient did not opt for pregnancy termination.

Findings:

  • The patient experienced a spontaneous abortion during the 12th week of gestation.
  • While risk factors like smoking and gravida status were present, the potential role of ustekinumab and psoriasis requires further investigation.

Implications:

  • This case underscores the need for pregnancy registries and large prospective studies.
  • Further research is crucial to determine if psoriasis, comorbidities, or ustekinumab contribute to adverse pregnancy outcomes.